Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4A1 | P60842 | 18/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.80 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.80 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | RELA | Q04206 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29531662 | 1.00 | EIF4A1 (0.80) | EIF4A1CYP3A4HIF1APAX8NFKB1 | |
| SCHEMBL20496143 | 1.00 | EIF4A1 (0.80) | EIF4A1CYP3A4HIF1APAX8NFKB1 | |
| SCHEMBL17414017 | 1.00 | EIF4A1 (0.80) | EIF4A1CYP3A4HIF1APAX8NFKB1 | |
| SCHEMBL29532286 | 1.00 | EIF4A1 (0.80) | EIF4A1CYP3A4HIF1APAX8NFKB1 | |
| SCHEMBL18836072 | 1.00 | EIF4A1 (0.80) | EIF4A1CYP3A4HIF1APAX8NFKB1 | |
| SCHEMBL17414014 | 1.00 | EIF4A1 (0.80) | EIF4A1CYP3A4HIF1APAX8NFKB1 | |
| SCHEMBL18836363 | 0.95 | EIF4A1 (0.82) | EIF4A1CYP3A4HIF1APAX8NFKB1 | |
| SCHEMBL29532114 | 0.95 | EIF4A1 (0.82) | EIF4A1CYP3A4HIF1APAX8NFKB1 | |
| SCHEMBL17414001 | 0.95 | EIF4A1 (0.82) | EIF4A1CYP3A4HIF1APAX8NFKB1 | |
| SCHEMBL18835988 | 0.94 | EIF4A1 (0.73) | EIF4A1CYP3A4HIF1APAX8NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210163513-A1 | Phospholipid-Flavagline Conjugates and Methods of Using the Same for Targeted Cancer Therapy | CELLECTAR BIOSCIENCES, INC. (US) | 2021-06-03 | — | — | US | disclosed |
| WO-2021072300-A1 | PHOSPHOLIPID-FLAVAGLINE CONJUGATES AND METHODS OF USING THE SAME FOR TARGETED CANCER THERAPY | CELLECTAR BIOSCIENCES, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163513-A1 | Phospholipid-Flavagline Conjugates and Methods of Using the Same for Targeted Cancer Therapy | PHOSPHO1, PLEC, PEBP1 | EIF4A1 4874/4885CYP3A4 1644/4885HIF1A 3892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.